[Effects of Xialiqi Capsules on the expressions of PCNA and caspase-3 in rats withbenign prostatic hyperplasia]

To explore the effects of Xialiqi Capsules(XLQ) on the expressions of the proliferating cell nuclear antigen (PCNA) and caspase-3 in the prostate tissue of the BPH rat model.

Fifty male SD ratswereequally randomized into groups A (sham operation control), B (BPH model control), C (high-dose XLQ), D (low-dose XLQ), and E (finasteridecontrol) andthe BPH modelswere established by subcutaneous injection of testosterone propionate at 0. 5 mg per kilogram of the body weight per day for 30 days after castration. After modeling, the animals in groups A and B were treated intragastricallywith normal saline, while those in C, D, and E with XLQ at 1.20 and 0.61 g per kilogram of the body weight per day or finasterideat 0.8 mg per kilogram of the body weight per day, respectively, all for 30 days. Then,the bilateral prostates were harvestedfrom the rats for calculation of the prostatic index (prostate wet weight/ body weight) and determination of the expressions of PCNA and caspase-3 in the prostate tissue by immunohistochemistry and immunofluorescence staining, respectively.

The prostate wet weight and prostate index were significantly increased in group B as compared with group A, ([1326±60] vs[471±17] g, P<0.01; [2.89±0.18] vs [1.06±0.06] mg/g, P<0.01), but decreased in groups C ([914±36] g;[2.02±0.08] mg/g), D ([1 099±46]g;[2.39±0.11] mg/g), and E ([817±53] g;[1.83±0.10] mg/g)in comparison with B (P<0.01), with statistically significant differences among groups C, D, and E(P<0.01) and most significantly in E.The PCNA level in the prostate tissue wasremarkably higher in group B than in A, but lower in groups C, D and E than in B. The expression of caspase-3 was down-regulatedin group B as compared with A, but up-regulated in groups C, D and E in comparison with B, most significantly in E.

Xialiqi Capsules can effectively reduce the prostate wet weight and prostatic index of in rats with BPH by inhibiting the level of PCNA and promoting the expression of caspase-3.

目的: 探讨夏荔芪胶囊对良性前列腺增生(BPH)模型大鼠增殖细胞抗原(PCNA)、半胱氨酸蛋白酶3(caspase-3)表达水平的影响。 方法: 50只雄性SD大鼠,随机分为5组,每组10只:空白组(假手术组),模型组,夏荔芪高、低剂量治疗组[1.20 g/(kg·d)、0.61 g/(kg·d)]及非那雄胺治疗组[0.8 mg/(kg·d)]。采用去势后皮下注射丙酸睾酮[0.5 mg/(kg·d),30 d],建立大鼠BPH模型。空白组及模型组予以生理盐水,治疗组予以相应药物,造模成功后连续灌胃30 d。实验结束后将各组大鼠于麻醉下留取双侧前列腺组织后处死,计算大鼠前列腺指数(前列腺湿重/体重);免疫组化法检测大鼠前列腺组织中PCNA的表达情况;免疫荧光法检测大鼠前列腺组织中caspase-3的表达水平。 结果: 与空白组相比,模型组的前列腺湿重(g)及前列腺指数(mg/g)明显增加(1.326±60 vs 471±17;2.89±0.18 vs 1.06±0.06,P均<0.01);与模型组比较,各治疗组的前列腺湿重及前列腺指数则明显降低,其中,夏荔芪高剂量组较低剂量组下降更明显(914±36 vs 1.099±46;2.02±0.08 vs 2.39±0.11,P均<0.01),而各治疗组中以非那雄胺组(817±53 vs 471±17;1.83±0.10 vs 1.06±0.06,P均<0.01)降低最明显。免疫组化结果显示,与空白组相比,模型组大鼠前列腺组织中PCNA表达明显增多,各治疗组与模型组相比,前列腺组织中PCNA表达均有明显减少,其中夏荔芪高剂量治疗组减少较为明显。免疫荧光结果显示,与空白组相比,模型组大鼠前列腺组织caspase-3表达量降低,各治疗组与模型组相比,前列腺组织中caspase-3表达明显增高,其中非那雄胺治疗组增高较为明显。 结论: 夏荔芪胶囊能明显降低BPH大鼠前列腺湿重及前列腺指数,通过降低前列腺组织中PCNA的表达水平,增高前列腺组织中caspase-3的表达,可能是其治疗BPH大鼠的机制。.

Zhonghua nan ke xue = National journal of andrology. 2017 Aug [Epub]

Hong-Cai Cai, Le-Bin Song, Guo-Wei Zhang, Xing-Rong Qing, Dun-Sheng Mo, Wei Liu, Xu-Xin Zhan, Yu-Feng Huang, Xue-Jun Shang

Department of Andrology, Jinling Hospital Affiliated to Southern Medical University / Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China., First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210009, China., Family Planning Research Institute/Center of Reproductive Medicine, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China., Department of Urology, Liuzhou Workers' Hospital / The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China., Department of Reproductive Medicine, Xi'an No.4 Hospital, Xi'an, Shaanxi 710004, China., Department of Andrology, Jinling Hospital Affiliated to Nanjing University School of Medicine / Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe